Current Practices and Clinical Implementation of Electronic Portal Imaging Device-based Dosimetry in Indian Radiotherapy Centres: A National Survey

印度放射治疗中心电子射野成像装置剂量测定的现状及临床应用:一项全国性调查

阅读:1

Abstract

PURPOSE: This study aims to assess the current prevalence, utilization patterns, and operational challenges of electronic portal imaging device (EPID)-based dosimetry systems in Indian radiotherapy centres. MATERIALS AND METHODS: A multiple-choice survey was distributed through Google Forms to medical physicists in India. The four-section survey covered treatment techniques, EPID availability and dosimetry, alternative detectors, and future challenges. Responses were limited to one per institution, with follow-up reminders. RESULTS: A total of 237 responses were received with a response rate of 62.2%. Among these, 73% of institutions currently use EPID-based dosimetry systems. Of these users, 42.2% rely on EPID for daily quality assurance (QA), and 62.4% of institutions use EPID for more than 50% of their total QA workflow. The primary tasks performed using EPID systems include patient-specific QA (PSQA) for intensity modulated radiation therapy (100%), periodic machine QA (58.4%), PSQA for stereotactic radiation therapy/stereotactic body radiation therapy (48.6%), machine commissioning (18.5%), and in vivo dosimetry (10.4%). Among institutions not currently using EPID due to nonavailability, 89.1% expressed willingness to adopt it for PSQA in the future. Major challenges in implementing EPID dosimetry were software limitations (34.2%) and maintenance and calibration issues (35.0%). After adopting EPID dosimetry, 79.8% of institutions observed improvements compared to conventional detectors. In addition, 93.7% of institutions believed that EPID dosimetry implementation would reduce physicist workload through automated software and resource optimization. CONCLUSION: This study reveals the widespread use of EPID systems and highlights that implementation offers certain advantages. However, issues such as software limitations, high initial cost, and the need for affordable or free resources remain barriers to wider adoption.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。